Weekly Research Analysts’ Ratings Changes for Innoviva (INVA)

Several analysts have recently updated their ratings and price targets for Innoviva (NASDAQ: INVA):

• 10/8/2025 – Innoviva had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 10/3/2025 – Innoviva was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 9/30/2025 – Innoviva is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “sell” rating and a $17.00 price target on the stock.
• 9/30/2025 – Innoviva is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “sell” rating and a $17.00 price target on the stock.
• 9/27/2025 – Innoviva had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 9/21/2025 – Innoviva was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 9/13/2025 – Innoviva was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 9/1/2025 – Innoviva was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 8/24/2025 – Innoviva was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 8/16/2025 – Innoviva was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 8/11/2025 – Innoviva is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $45.00 price target on the stock.
• 8/11/2025 – Innoviva had its price target raised by analysts at HC Wainwright from $40.00 to $45.00. They now have a “buy” rating on the stock.

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.